Clinical Trials – Mineralys Therapeutics

Lorundrostat Development Program

At Mineralys Therapeutics, we are focused on developing medicines to target diseases driven by abnormally elevated aldosterone.

uHTN = uncontrolled hypertension; rHTN = resistant hypertension; CKD = chronic kidney disease